ClinicalTrials.gg
RecruitingNCT06748885Updated Oct 8, 2026

Mpact 3D Metal Monolit Study

An observational study in Total Hip Arthroplasty (THA), sponsored by Medacta International SA. Recruiting at 3 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Medacta International SA · Observational

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
88
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Total hip arthroplasty (THA) is one of the most common operations performed in orthopaedics to improve a patient's quality of life.

Surgeons are constantly seeking to improve all aspects of care related to this procedure, whether it be improving implant technology, improving instrumentation or the technique involved in performing the procedure.

In recent years, a new porous titanium coating has been introduced to promote good osseointegration of uncemented cups. High friction torque and a feeling of immediate anchorage provide excellent primary stability, while high porosity ensures bone growth providing secondary stability. With higher porosity than standard coatings, a greater volume of bone can be present in the porous surface, giving a proportional increase in force at the interface. he Mpact 3D Metal Monolith cup has been designed to provide greater range of motion and improved joint stability, with a reduced risk of dislocation. It is an innovative design that improves stability and provides a favourable environment for long-term biological metal-bone fixation.

The current study aims to collect clinical and radiological data to assess the function of the operated hip and the stability of the Mpact 3D Metal Monolith cup at 2 years and survival at 5 years for the treatment of patients requiring hip arthroplasty.

02

Conditions studied

  • Total Hip Arthroplasty (THA)
03

In context

Lead sponsor

Medacta International SA is the lead sponsor of 46 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who meet the inclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient with a disease that corresponds to the indications for use of Medacta implants (according to the instructions for use)
  2. Patient eligible for primary total hip arthroplasty
  3. Patient aged between 18 and 75 years
  4. Patient covered by the French Social Security system or an equivalent protection scheme.
  5. Patient able, in the investigator's opinion, to comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. Patient suffering from inflammatory arthritis
  2. Previously operated hip
  3. Patient requiring a transplant
  4. Hip tumour involved
  5. Patient with progressive local or systemic infection
  6. Severe acetabular dysplasia
  7. Patient with muscle loss, neuromuscular disease or vascular impairment of the affected limb.

4. Patient with known medical problems that may compromise independent recovery of mobility 5. Patient with a greater than 40 kg/m². 6. Patient with major cognitive impairment that prevents him/her from fully understanding the requirements of the study 7. Patient living in a geographical area where study follow-up is not possible. 8. Patient taking part in interventional research 9. Minor patient 10. Protected adult patient 11. Vulnerable person according to article L1121-6 of the Public Health Code

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
88 participants (estimated)
Patient registry
No

Interventions

  • DeviceMpact 3D Metal Monolith

    THA with Mpact 3D Metal Monolith

06

What researchers measure

Primary outcomes

  1. Evaluation of the hip function

    The Harris Hip Scale (HHS) was developed for the assessment of the results of hip surgery, and is intended to evaluate various hip disabilities and methods of treatment in an adult population. The original version was published 1969\[1\]. The HHS is an outcome measure administered by a qualified health care professional, such as a physician or a physical therapist. The HHS is a measure of dysfunction so the higher the score, the better the outcome for the individual. Results can be recorded and calculated online. The maximum score possible is 100. Results can be interpreted with the following: \<70 = poor result; 70-80 = fair, 80-90 = good, and 90-100 = excellent.

    Time frame: Preoperative, 3 months, 6 months, 1 year, 2 years, 5 years

Secondary outcomes

  1. Analysis of the primary stability of the implant at 2 years

    Protocol EBRA-Cup: Measurement of longitudinal/transversal migration of acetabular cup in digital serial radiographs (minimum of 4 x-rays per series). Full size AP pelvis radiographs are required. Accuracy: +/- 1mm.

    Time frame: 2 years

  2. Analysis of the wear of the polyethylene insert (HighCross) at 2 years

    Martell method of linear wear measurement

    Time frame: 2 years

  3. Evaluation of the fixation and osteolysis

    Radiological analysis

    Time frame: Immediate postoperative, 3 months, 6 months, 1 year, 2 years, 5 years

  4. Evaluation of the mobility

    The Oxford Hip Score (OHS) is a joint-specific, patient-reported outcome measure designed to assess disability in patients undergoing total hip replacement. The OHS is a short 12-item survey that can be done with pen and paper. Patients are asked to reflect on their pain and functional ability over the previous four weeks. There are two domains (pain and function) with six items or questions in each. Each item has five possible responses. In the original scoring responses were from 1 = least difficult to 5= most difficult. Item scores are summed to give a total score from anywhere between 12 and 60. The lower the score, the better the outcome.

    Time frame: Preoperative, 3 months, 6 months, 1 year, 2 years, 5 years

  5. Evaluation of the safety of the implant

    Collection of intraoperative and postoperative complications

    Time frame: Intraoperative, immediate postoperative, 3 months, 6 months, 1 year, 2 years, 5 years

  6. Evaluation of the survival of the implant

    Kaplan-Meier survival method

    Time frame: 3 months, 6 months, 1 year, 2 years, 5 years

07

Study locations

1 of 3 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2024 (actual). Primary completion is estimated for Dec 2030, 82 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2024
First posted
Dec 27, 2024
StartActual
Feb 28, 2024
Primary completionEst.
Dec 2030
CompletionEst.
Dec 2030
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and criteria formatting
1 update, last Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Minor edits only
    + 2 other changes: verification date and criteria formatting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06748885
Responsible party
Sponsor
First posted
Dec 27, 2024
Start date
Feb 28, 2024
Primary completion
Dec 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
Oct 8, 2026

Study contacts

Philippe Anract
Contact
philippe.anract@aphp.fr
01 58 41 30 38

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion